0001551152 false Common Stock, $0.01 Par Value ABBV 0001551152 2022-10-12 2022-10-12 0001551152 us-gaap:CommonStockMember exch:XNYS 2022-10-12 2022-10-12 0001551152 exch:XCHI us-gaap:CommonStockMember 2022-10-12 2022-10-12 0001551152 abbv:SeniorNotes1.500Percentdue2023Member exch:XNYS 2022-10-12 2022-10-12 0001551152 abbv:SeniorNotes1.375Percentdue2024Member exch:XNYS 2022-10-12 2022-10-12 0001551152 abbv:SeniorNotes1.250Percentdue2024Member exch:XNYS 2022-10-12 2022-10-12 0001551152 abbv:SeniorNotes0.750Percentdue2027Member exch:XNYS 2022-10-12 2022-10-12 0001551152 abbv:SeniorNotes2.125Percentdue2028Member exch:XNYS 2022-10-12 2022-10-12 0001551152 abbv:SeniorNotes2.625Percentdue2028Member exch:XNYS 2022-10-12 2022-10-12 0001551152 abbv:SeniorNotes2.125Percentdue2029Member exch:XNYS 2022-10-12 2022-10-12 0001551152 abbv:SeniorNotes1.250Percentdue2031Member exch:XNYS 2022-10-12 2022-10-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares






Washington, D.C. 20549







Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): October 12, 2022



(Exact name of registrant as specified in its charter)


Delaware   001-35565   32-0375147
(State or other Jurisdiction
of Incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)





1 North Waukegan Road

North Chicago, Illinois 60064-6400

(Address of principal executive offices)(Zip Code)


Registrant’s telephone number, including area code: (847) 932-7900


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.01 Par Value   ABBV   New York Stock Exchange
Chicago Stock Exchange
1.500% Senior Notes due 2023   ABBV23B   New York Stock Exchange
1.375% Senior Notes due 2024   ABBV24   New York Stock Exchange
1.250% Senior Notes due 2024   ABBV24B   New York Stock Exchange
0.750% Senior Notes due 2027   ABBV27   New York Stock Exchange
2.125% Senior Notes due 2028   ABBV28   New York Stock Exchange
2.625% Senior Notes due 2028   ABBV28B   New York Stock Exchange
2.125% Senior Notes due 2029   ABBV29   New York Stock Exchange
1.250% Senior Notes due 2031   ABBV31   New York Stock Exchange


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company ¨


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨






Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


Laura J. Schumacher, Vice Chairman, External Affairs and Chief Legal Officer, informed AbbVie that she plans to retire from the company after a period of transition. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.


Item 9.01. Financial Statements and Exhibits.


Exhibit No.   Exhibit
99.1   Press Release dated October 17, 2022
104   The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: October 17, 2022 By: /s/ Timothy J. Richmond
      Timothy J. Richmond
      Executive Vice President, Chief Human Resources Officer




Exhibit 99.1





Perry Siatis Named as Executive Vice President, General Counsel and Secretary


NORTH CHICAGO, Ill., October 17, 2022 -- AbbVie (NYSE: ABBV) announced today that Laura J. Schumacher, vice chairman of external affairs and chief legal officer, will retire from the company after a period of transition, following a distinguished 32-year career at AbbVie and its predecessor company Abbott. The company also announced that Perry C. Siatis, who currently serves as senior vice president and deputy general counsel, will assume the role of executive vice president, general counsel and secretary.


“It is difficult to overstate the extraordinary impact Laura has had on AbbVie over the past 10 years,” said Richard A. Gonzalez, chairman and chief executive officer of AbbVie. “Laura was instrumental in the creation of AbbVie in 2013, helping to shape the strategy, structure and culture that have made us so successful as a company today. Although she is clearly one of the finest legal minds in the industry and has spearheaded any number of complex legal and regulatory issues for us, her contributions to AbbVie go far beyond the legal department. I have relied on her as a trusted strategic counselor and invaluable colleague. The entire Board of Directors joins me in wishing her all the best in her retirement from the company.”


“We are fortunate to have a deep bench of talent at AbbVie, and I am delighted that Perry will serve as executive vice president, general counsel and secretary,” continued Mr. Gonzalez. “Perry is the optimal choice to build on Laura’s successes. He has contributed significantly to our growth since joining AbbVie in 2005, leading our ethics and compliance programs and strategic initiatives in areas, such as mergers and acquisitions, litigation, licensing and intellectual property. I look forward to working even more closely with Perry.”





In AbbVie’s separation from Abbott, Ms. Schumacher built and led the company’s award-winning global Legal function as well as all externally facing functions, including Communications, Corporate Marketing, Government Affairs, Global Philanthropy, Ethics and Compliance, as well as Health Economics and Outcomes Research. She led the creation of AbbVie’s brand and corporate identity and leads teams that manage its communications and government affairs programs. Ms. Schumacher has identified and led the execution of multiple transactions to support the company’s business development efforts, including the $63 billion acquisition of Allergan in 2020. She established the AbbVie Foundation and led the company’s groundbreaking philanthropy strategy, including AbbVie’s more than $550 million in charitable contributions since the company’s inception in 2013. Ms. Schumacher also created AbbVie’s industry-leading Diversity in Law program, which significantly increased representation throughout the organization and with external Law firm partners. Prior to AbbVie’s separation from Abbott, Ms. Schumacher enjoyed a 22-year career at Abbott in a variety of leadership positions.


Perry C. Siatis joined the legal department of Abbott Laboratories in 2005 and advanced through a series of leadership roles with increasing responsibility at Abbott, and then AbbVie. In his over 17 years with the company, Mr. Siatis has led teams throughout the Legal department with a focus on finding innovative solutions to complex legal issues to better serve patients. In his current role, Mr. Siatis is responsible for overseeing and providing legal guidance for commercial, transactional, R&D, and litigation matters around the world, as well as corporate governance. Among his many significant achievements, Mr. Siatis has developed and implemented the litigation, intellectual property, and legal strategy for several of the company’s key products over the years, as well as provided strategic legal advice for significant transactions the company has made. Mr. Siatis has also served as chief compliance officer.


About AbbVie


AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology and gastroenterology, in addition to products and services across our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook or LinkedIn.





Frank Benenati
(224) 688-4169


Liz Shea
(847) 935-2211